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INTRODUCTION
Proton pump inhibitors (PPIs) are more potent
than histamine H2 receptor antagonists (H2 block-
ers) in terms of their ability to inhibit gastric acid
secretion while also promoting the healing of gas-
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Abstract :
AIM : Prostaglandins (PGs) and leukotrienes (LTs) are major factors involved in the
defense of the gastric mucosa against ulcer formation. However, little is still known about
the gastromucosa-protecting action of proton pump inhibitors (PPIs) and histamine H2
receptor antagonists (H2 blockers) in patients with gastric ulcer. We therefore examined
the effectiveness of a PPI in protecting the gastric mucosa.
METHODS : We compared the PGE2 and LTB4 levels and the expression levels of cyclooxy-
genase (COX)-1 and COX-2 mRNA in the gastric mucosa in gastric ulcer patients between
the group treated for 8 weeks with a PPI, rabeprazole (PPI group ; n=5), and the group
treated for 8 weeks with an H2 blocker, ranitidine (H2 blocker group ; n=6), as well as in
nonulcer subjects (control group ; n=5).
RESULTS : The mucosal levels of PGE2 and COX-2 mRNA expression were significantly
lower in the ulcer patients than those in the nonulcer patients, whereas the LTB4 level
was significantly higher in the ulcer patients than that in the nonulcer patients, and it
was also significantly lower in the ulcerated mucosa than that in the nonulcerated mu-
cosa. The PPI group had a significantly increased PGE2 and decreased LTB4 levels in
comparison to the H2 blocker group during the ulcer-healing stage. The COX-1 mRNA ex-
pression showed no difference among the PPI and H2 blocker groups or between before
and after the treatment. However, the COX-2 mRNA expression increased in the PPI
group more than that in the H2 blocker group during the ulcer-healing stage.
CONCLUSION : These findings demonstrated the significant gastric-mucosa-protecting
effect of PPI by increasing the PGE2 production and reducing the LTB4 production. J. Med.
Invest. 54 : 83-90, February, 2007
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tric ulcers(1). PPIs block the final step in acid se-
cretion from gastric parietal cells. Rabeprazole is a
substituted benzimidazole PPI. In addition to its
inhibitory effect on gastric acid secretion, rabeprazole
has been reported to prevent gastric mucosal dam-
age such as that resulting from ethanol or aspirin
administration in animal models(2-4). Lansopra-
zole, one of PPIs, has also been reported to induce
gastric mucosal protection through up-regulation
of cyclooxygenase (COX)-2 with endogenous
prostaglandin (PG) synthesis in an animal model
of gastric mucosal injury(5). COX is the enzyme
that catalyzes the committed step in the metabo-
lism of arachidonic acid to PGs(6). Two isoforms
of COX exist : including constitutively expressed
COX-1 and inducible COX-2 in stomach. PGs play
an important role in the gastric mucosal defense
(7). It should be noted that increased PG synthe-
sis via the COX-2 expression and decreased leu-
kotriene (LT) synthesis in the gastric mucosa may
be involved in mucosal cytoprotection(8). LTs be-
long to a group of proinflammatory mediators de-
rived from arachidonic acid(9, 10). However, little is
still known about the gastromucosa-protecting action
of PPIs and H2 blockers in patients with gastric ulcer.
We experienced a case who demonstrated a very
large gastric ulcer which perforated the abdominal
wall and had been caused by diclofenac, a nonster-
oidal anti-inflammatory drug (NSAID)(11). In this
case, since conservative treatment by the oral ad-
ministration of the H2 blocker ranitidine and a PG
preparation did not show any sign of closure of the
perforation, ranitidine was replaced by rabeprazole.
Thereafter, the mucosal regeneration progressed
rapidly, the perforation closed, and the ulcer com-
pletely healed. These findings suggested that not
only the PG preparation but also rabeprazole thus
appears to promote cytoprotection against the gas-
tric mucosal injury. Therefore, in order to clarify the
differences between the gastromucosa-protecting
actions of rabeprazole and ranitidine in patients with
gastric ulcer, we administered either rabeprazole
or ranitidine to patients having their first episodes
of gastric ulcer for 8 weeks and then comparatively
evaluated the expression of gastric mucosal COX
and the secretory kinetics of PGs and LTs. To bal-
ance the background of damage to the gastric mu-
cosa, the subjects were limited to patients who were
positive for Helicobacter pyroli (Hp).
SUBJECTS AND METHODS
Subjects
From September 2000 to December 2002, the
study was conducted at Tokushima Prefecture
Miyoshi Hospital. The subjects consisted of 11 pa-
tients who demonstrated their first episode of
gastric ulcer with no previous history of the disease
in whom a single acute stage (A1 or A2) ulcer was
located at the gastric angle without any bleeding,
and the presence of Hp was confirmed by the 13C-
urea breath test (Otsuka Pharmaceutical Co., Tokyo)
at the first endoscopy. The patients with acute gas-
tric ulcers were divided at random into age- and sex-
matched 2 groups. Five patients (4 males and 1 fe-
male ; mean age ± SD, 54.4 ± 12.4 years ; PPI group)
were administered rabeprazole (10 mg/day), while
6 (5 males and 1 female ; 53.3 ± 12.6 years ; H2
blocker group) were administered ranitidine (300
mg/day) for 8 weeks. The control group without
any episode of gastric ulcer comprised 5 subjects
(4 males and 1 female ; 55.2 ± 11.9 years) who were
all positive for Hp . In the PPI group, one had dia-
betes mellitus, and one had bronchial asthma as
complications of gastric ulcer. In the H2 blocker
group, one had hypertension, one had diabetes mel-
litus, and one had chronic bronchitis as complica-
tions. In the control group without any episode of
gastric ulcer, one had hypertension and one had dia-
betes mellitus. The oral treatments for these com-
plications were continued. The ulcer diameters and
the blood hemoglobin levels at the first endoscopy
were similar in all groups (Table 1). No patient had
taken NSAIDs, PPIs, H2 blockers, PG preparations,
or antibiotics prior to enrollment in this study. Pa-
Table 1. Clinical characteristics of gastric ulcer patients (PPI and H2 blocker groups) and nonulcer subjects (control group) with
Hp infection
PPI H2 blocker Control P values
Male/female 4/1 5/1 4/1 NS
Age (years) 54.4 ± 12.4 53.3 ± 12.6 55.2 ± 11.9 NS
Diameter of gastric ulcer (cm) 1.2 ± 0.4 1.1 ± 0.4 Not detected NS
Blood hemoglobin level (g/dl) 15.9 ± 2.7 15.8 ± 2.4 15.5 ± 3.1 NS
Values are the means ± SD (n = 5 or 6).
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tients with gastric or other cancers, liver disease, re-
nal dysfunction, or duodenal ulcer were excluded.
Informed consent was obtained from all of the sub-
jects.
METHODS
At endoscopic examinations performed in the
control group and in the antisecretory agents-groups
before and at 8 and 12 weeks after beginning the ad-
ministration of the antisecretory agents, tissue sam-
ples were collected both from the edge of the ulcer
on the gastric angle (ulcerated areas) and the lower
gastric body on the greater curvature (nonulcer-
ated areas), and were immediately stored at -80C
until assayed. The concentrations of PGE2, 6-keto
PGF1a, which is a metabolic product of stable PGI2,
and LTB4, and the gene expressions of COX-1 and
COX-2 were examined in the gastric mucosa. Hp
elimination treatment was performed at 12 weeks
or more after beginning the administration of the
antisecretory agents.
The biopsy specimens were homogenized in a
Polytron PCU homogenizer (Kinematica, Luzern,
Switzerland), the PGE2 and 6-keto PGF1a concen-
trations were determined using radioimmunoas-
say kits (Amersham, Little Chalfont, UK), and the
LTB4 concentration was determined using an en-
zyme immunoassay kit (Amersham). The protein
concentration was determined by the Lowry pro-
tein assay. For RNA extraction from gastric mucosal
tissue specimens after pooling the samples from the
ulcerated and nonulcerated areas, 10 mg of the fro-
zen gastric mucosal tissue was homogenized with a
glass homogenizer in 200μl of RNA zolTM B (Biotex
Laboratories, Friendswood, TX, USA) at 4C. Twenty
microliters of phenol/chloroform were then added
to the mixture and the aqueous phase was collected
after centrifugation at 12,000 X g at 4C for 15 min-
utes. The RNA was precipitated with an equal vol-
ume of isopropanol and then it was washed with 75%
ethanol. RNA pellets were resuspended in 20 μl of
diethylpyrocarbonate-treated distilled water and stored
at -80C. For the analysis of COX-2 mRNA and COX-
1 mRNA expression, RT-PCR was performed using
a one-step RNA PCR kit (AMV). Briefly, 1 μg of
total RNA for each sample was added to a PCR re-
action. After reverse transcription (30 min at 50 C ;
2 min at 94 C), 30 cycles of amplifications (1 min
at 94 C ; 1 min at 50 C ; 1 min at 72 C) were per-
formed. The linear range for PCR was found to be
between 20 and 40 cycle. The PCR products were
separated on 2% agarose gel containing 0.5 μg/ml
of ethidium bromide. The oligonucleotides, 5’-
TGCCCAGCTCCTGGCCCGCCGCTT-3’ and 5’-
GTGCATCAACAGGCGCCTCTTC-3’ were used for
amplification of the 303 bp fragment of human
COX-1 mRNA(12). The oligonucleotides, 5’-
TTCAAATGAGATTGTGGGAAAAT-3’ and 5’-
AGATCATCTCTGCCTGAGTATCTT-3’ were used
for amplification of the 305 bp fragment of human
COX-2 mRNA(12). Yeast transfer RNA was used
as negative controls. Beta-actin gene expression was
monitored for the control of mRNA loading. The ex-
pression intensities of COX-2 mRNA and COX-1
mRNA were evaluated by scanning densitometry
(Gel Doc 1000UV, Richmond, CA, USA) in compari-
son to the intensity of beta-actin gene expression.
Statistical analysis
The results are expressed as the means ± SD.
Differences between the groups were assessed by
Student’s t test. P values of <0.05 were considered
to be significant.
RESULTS
In the PPI and H2 blocker groups of gastric ulcer
patients with Hp infection before treatment with the
antisecretory agents, the concentrations of PGE2
(Fig. 1) and 6-keto PGF1a (Fig. 2) in the gastric mu-
cosa were significantly lower than those in the con-
trol group of nonulcer subjects with Hp infection,
although the 6-keto PGF1a concentration in the
Fig. 1. Changes in the gastric mucosal levels of PGE2 after
treatment with rabeprazole (PPI group) or ranitidine (H2 blocker
group)
The gastric ulcer base disappeared at 8 － 12 weeks after treat-
ment. The samples were obtained from the gastric mucosa in
ulcer patients and nonulcer subjects (control group). Values are
the means ± SD (n = 5 or 6). *P <0.05 in comparison with the
control group. +P <0.05 in comparison with the H2 blocker group.
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nonulcerated gastric mucosa in ulcer patients did
not show a significant decrease (Fig. 2). All of gas-
tric ulcers had been already scarred (S2) 8 weeks
after treatment with the antisecretory agents. Dur-
ing gastric ulcer healing, the PGE2 concentration
in the PPI group after 8 weeks increased significantly
more than that in the H2 blocker and control groups,
and then returned after 12 weeks to a level similar
to that in the H2 blocker and control groups (Fig. 1).
The 6-keto PGF1a concentration in the ulcerated
gastric mucosa in ulcer patients returned after 8
weeks to a level similar to that in the nonulcerated
mucosa in both the ulcer patients and nonulcer sub-
jects (Fig. 2). Whereas the LTB4 (Fig. 3) concen-
tration in ulcer patients before the antisecretory
agent treatment was significantly higher than in
that in nonulcer subjects, and it was significantly
lower in the ulcerated mucosa than that in the nonul-
cerated mucosa. During gastric ulcer healing, the
LTB4 concentration of the ulcer-scarred and nonul-
cerated mucosa in the PPI group after 8 weeks de-
creased significantly more than that in the H2 blocker
and control groups without any significant differ-
ence between in the ulcer-scarred and nonulcerated
mucosae, and then it returned after 12 weeks to a
level similar to that in the H2 blocker and control
groups (Fig. 3).
The COX-1 mRNA expression level in the gas-
tric mucosa showed no difference among the PPI,
H2 blocker and control groups or between before
and after the treatment (Fig. 4). However, the COX-
2 mRNA expression level in the gastric mucosa in
ulcer patients was significantly reduced before the
treatment in comparison with that in nonulcer sub-
jects. Moreover, the relative densities of COX-2
PCR bands at 8 weeks were 2.8 times and 2.1 times
increased in the PPI group and in the H2 blocker
group, respectively, and the increase was signifi-
Fig. 2. Changes in the gastric mucosal levels of 6-keto PGF1α
after treatment with rabeprazole (PPI group) or ranitidine (H2
blocker group)
The gastric ulcer base disappeared at 8 － 12 weeks after treat-
ment. The samples were obtained from the gastric mucosa in ul-
cer patients and nonulcer subjects (control group). Values are
the means ± SD (n = 5 or 6). *P <0.05 in comparison with the
control group.
Fig. 3. Changes in the gastric mucosal levels of LTB4 after
treatment with rabeprazole (PPI group) or ranitidine (H2
blocker group)
The gastric ulcer base disappeared at 8 - 12 weeks after treat-
ment. The samples were obtained from the gastric mucosa in
ulcer patients and nonulcer subjects (control group). Values
are the means ± SD (n = 5 of 6). *P <0.05 in comparison with
the control group. +P <0.05 in comparison with the H2 blocker
group. #P <0.05 in comparison with the nonulcerated area in
the same group of ulcer patients.
Fig. 4. Changes in the gastric mucosal expressions of COX-1
mRNA after treatment with rabeprazole (PPI group, A) or rani-
tidine (H2 blocker group, B)
The samples were obtained from the gastric mucosa in ulcer
patients and nonulcer subjects (control group). Both tissue speci-
mens obtained from the ulcerated and nonulcerated areas were
mixed for RNA extraction. The levels of COX-1 gene expres-
sion (303 bp) and β -actin gene expression (125 bp) were ana-
lyzed by RT-PCR. The results of a densitometric analysis are pre-
sented as the mean percentages of the signal intensity of β -actin
for COX-1 mRNA expression (C). Values are the means ± SD
(n = 5 or 6).
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cantly greater in the PPI group. The COX-2 gene
expression level in the PPI group returned after 12
weeks to a level similar to that in the H2 blocker
and control groups (Fig. 5).
DISCUSSION
PGs, which are mucosal protective factors, have
an antisecretory effect as well as a mucosa-protecting
effect(7, 13). PGs are produced from arachidonic
acid released from phospholipids of biological mem-
branes by the action of phospholipase. Phospholip-
ids metabolize into PGs and LTs by the COX and
lipoxygenase pathways, respectively. While COX-1
acts as a housekeeping enzyme in the gastric mu-
cosa and platelets, COX-2, the expression of which
is induced by agents including cytokines in such
cells as macrophages and neutrophils, is known to
play a role in inflammation and cell proliferation.
NSAIDs reduce the PG production by inhibiting
the expression of COX-1 and COX-2 in the gastric
mucosa and by increasing LTs in relative terms
(14). A decrease in PGs depresses various factors
in the gastric mucosal defense system, and an in-
crease in LTs enhances the radical production while
also exacerbating damage to the gastric mucosa
(15). This study was initiated from based on the
hypothesis that PPI promotes the healing mecha-
nism of the gastric mucosa via the secretory kinet-
ics of PGs and LTs by exerting some effect on the
COX expression in not only NSAID-induced gastric
ulcers, which we experienced(11), but also in com-
mon gastric ulcers. The mucosal protecting effects
of PGs against various agents that induce damage
to the gastric mucosa are called cytoprotection. PGs
produce effects such as directly protecting cells and
promoting cytotaxis in the luminal cavity, epithe-
lial, and subepithelial levels(14). Particularly, PGE2
increases the mucosal blood flow, promotes mu-
cus secretion, and increases bicarbonate secretion
(16), while PGI2 suppresses gastric acid secretion
(17). In addition, Hp infection is associated with an
increased production of PGE2 in the gastric mucosa
(18). Hp infection elicits persistent neutrophil infil-
tration in the gastric mucosa. The COX-2 expres-
sion by the neutrophils results in PGE2 synthesis
(19). In this study, the PGE2 and 6-keto PGF1a (a
metabolic product of stable PGI2) concentrations in
ulcer patients with Hp infection decreased during
the active-ulcer stage, and thereafter increased dur-
ing the ulcer-healing stage after treatment with PPI
and H2 blocker to a level similar to those in nonul-
cer subjects with Hp infection. Moreover, the in-
crease in the PGE2 concentration after 8 weeks,
when the gastric ulcers had been already scarred,
was significantly greater in the PPI group than in the
H2 blocker group. In contrast, the 6-keto PGF1a con-
centration after 8 weeks showed no significant dif-
ference between the PPI, H2 blocker and control
groups, when comparing the findings before and
after the treatment.
Kobayashi, et al. reported the PG levels to in-
crease at 4 and 7 days post-polypectomy in patients
in whom gastric ulcers were produced by an elec-
tric burning resection of gastric polyps, while the
most remarkable increase took place in the mucosa
along the ulcer margin rather than the mucosa far
from the ulcer site(20). In the present study, how-
ever, the PGE2 and 6-keto PGF1a levels were the
lowest during the active-ulcer stage with no signifi-
cant difference between the ulcerated and nonul-
cerated mucosae, although the 6-keto PGF1a level
in the ulcerated mucosa was significantly lower than
that in the control group. In addition, Kobayashi, et
Fig. 5. Changes in the gastric mucosal expressions of COX-2
mRNA after treatment with rabeprazole (PPI group, A) or rani-
tidine (H2 blocker group, B)
The samples were obtained from the gastric mucosa from both
ulcer patients and nonulcer subjects (control group). Both tis-
sue specimens obtained from the ulcerated and nonulcerated
areas were mixed for RNA extraction. The levels of COX-2
gene expression (305 bp) and β -actin gene expression (125 bp)
were analyzed by RT-PCR. The results of a densitometric analysis
are presented as the mean percentages of the signal intensity of
β -actin for COX-2 mRNA expression (C). Values are the means
± SD (n = 5). *P <0.05 in comparison with the control group.
+P <0.05 in comparison with the H2 blocker group.
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al. also reported that the PGE2 level in chronic
gastric ulcer patients was not significantly differ-
ent from that in normal subjects(21). Since chronic
Hp infection is accompanied by a persistent mu-
cosal production of PGE2(18), the PG production
mechanisms might therefore be depleted when a
gastric ulcer breaks out, although this study could
not show any comparative information on the de-
gree of gastric mucosal inflammation between the
gastric ulcer groups.
LTs are synthesized in leukocytes as arachidonic
acid is metabolized by lipoxygenase. An increase in
LTs enhances the radical production and aggra-
vates damage to the gastric mucosa(22). LTC4, LTD4,
and LTE4 enhance capillary permeability and pro-
mote airway mucosal secretion. LTB4 promotes leu-
kocytotaxis(23). In our study, the LTB4 concentra-
tion increased during the active-ulcer stage in ulcer
patients, and it decreased during the ulcer-healing
stage after the treatment. The decrease in the LTB4
concentration of the ulcer-scarred and nonulcerated
mucosae was significantly greater in the PPI group
than in the H2 blocker group after 8 weeks, thus sug-
gesting that PPI could reduce the LTB4 production
in the stomach.
COX-1 is routinely expressed in the normal gas-
tric mucosa, but COX-2 is expressed in the lamina
propria mucosae in the gastric mucosa infected by
Hp(24, 25). In experimental erosion or ulcer cre-
ated in animals, COX-2 mRNA and COX-2 protein
have been reported to be expressed in ulcer mar-
gins, while a COX-2 inhibitor was said to delay the
cure of ulcers(26, 27). Although whether selective
COX-2 inhibitors could induce directly gastrointes-
tinal ulceration remains to be elucidated, these find-
ings suggest that COX-2 could play an important
role in the repair of gastric ulcers by regulating PG
biosynthesis. In this study, gastric ulcer patients with
Hp infection showed significant difference in the
COX-2 mRNA expressions between the acute and
scarring phases during gastric ulcer healing. The
mucosal expression of COX-2 mRNA increased 2.8
times at 8 weeks after the beginning of the treat-
ment in the PPI group, and this increase was sig-
nificantly greater than that in the H2 blocker group.
The COX-1 gene expression showed no significant
difference between the PPI and H2 blocker groups
or when comparing the findings before and after the
treatment.
These results suggest that rabeprazole has a
mucosa-protecting effect on the healing process of
ulcers by increasing the PGE2 production and re-
ducing the LTB4 production. In addition, rabepra-
zole has an unique pharmacological ability to aug-
ment the production of gastric mucus and mucin
which thus generate the so-called mucus buffer
layer covering the gastric mucosa(28). PPIs have
been reported to inhibit radical production and
inflammation by suppressing the neutrophil activ-
ity(29-31). Akimoto, et al. reported that rabeprazole
is able to promote vessel regeneration and matura-
tion, thereby facilitating ulcer healing(32). In ulcer
patients, the increase of basic fibroblast growth
factor was reported to be greater with PPIs than H2
blockers(33). Although the mechanisms by which
rabeprazole induces COX-2 and PGE2 production and
reduces LTB4 production remain to be elucidated in
gastric ulcer patients with Hp infection, it is con-
sidered to promote the healing of ulcers due to these
mucosa-protecting actions in addition to its antise-
cretory action.
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